Encinitas, CA, United States of America

Ralph Bradshaw

This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Trefoil Therapeutics, Inc.. Active years: 2022-2026.


% Patents Active = 50.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2022-2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ralph Bradshaw: Innovator in Fibroblast Growth Factors

Introduction

Ralph Bradshaw is a notable inventor based in Encinitas, CA. He has made significant contributions to the field of biomedical research, particularly in the development of modified fibroblast growth factors. With a total of 2 patents, his work has the potential to impact therapeutic applications significantly.

Latest Patents

One of Ralph Bradshaw's latest patents is titled "Recombinant Modified Fibroblast Growth Factors and Therapeutic Uses Thereof." This patent describes modified fibroblast growth factor (FGF) polypeptides, along with pharmaceutical compositions and medicaments that incorporate these modified FGF polypeptides. The methods outlined in this patent aim to treat or prevent conditions that can benefit from the administration of FGFs.

Career Highlights

Ralph Bradshaw is currently associated with Trefoil Therapeutics, Inc., where he continues to advance his research and innovations. His work focuses on the therapeutic applications of fibroblast growth factors, which are crucial in various medical treatments.

Collaborations

Ralph collaborates with esteemed colleagues, including David Eveleth and Jennifer Jenkins-Eveleth. Their combined expertise enhances the research and development efforts at Trefoil Therapeutics, Inc.

Conclusion

Ralph Bradshaw's contributions to the field of fibroblast growth factors exemplify the impact of innovative research on therapeutic advancements. His patents and ongoing work continue to pave the way for new medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…